This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Coronavirus Vaccine Makers Now in Phase III as J&J Begins Study
by Kinjel Shah
COVID-19 vaccine candidates of four companies - J&J, Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna - are now in late-stage development.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Axsome Expedites Development Plan for Narcolepsy Candidate
by Zacks Equity Research
Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.
AstraZeneca's Lynparza Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, nears approval as a treatment for prostate cancer, and first-line maintenance treatment for ovarian cancer in combination with Avastin in Europe.
Roche Buys NLRP3 Inflammasome Inhibitors Developer Inflazome
by Zacks Equity Research
Roche (RHHBY) buys Inflazome for ???euro 380 million and gains access to pipeline of small molecule NLRP3 inhibitors.
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.02, moving -1.67% from the previous trading session.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
by Ritujay Ghosh
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
by Kinjel Shah
AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4
by Zacks Equity Research
The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.
Novavax Expands Coronavirus Vaccine Manufacturing Deal in India
by Zacks Equity Research
Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.
BioNTech Gets New Funding for Coronavirus Vaccine Development
by Zacks Equity Research
BioNTech (BNTX) receives grant of up to almost $445 million to support development and potential approval of its coronavirus vaccine candidate.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.96, moving -0.14% from the previous trading session.
3 Stocks to Buy Now for Growth & Dividends to Counter Low Bond Yields
by Benjamin Rains
Investors might want to consider buying stocks that also provide income via dividends given the current interest rate environment...
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
ETFs in Focus on Tug of War Between Bulls and Bears
by Sweta Killa
Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.
Pfizer Seeks to Raise Coronavirus Study Enrollment Target
by Zacks Equity Research
Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.
AstraZeneca Resumes UK Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in U.K. resume after the Medicines Health Regulatory Authority confirms that it is safe to do so.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.
Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Pausing of AstraZeneca's Coronavirus Study Aids Pfizer, Moderna
by Indrajit Bandyopadhyay
The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.
3 Safe Blue Chip Stocks to Buy as Market Bounces Back After Tech Selloff
by Benjamin Rains
There could be more selling ahead and the election might cause turbulence. Nonetheless, long-term investors might want to consider adding a few safe blue chip stocks to their portfolios...
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.18, marking a +0.7% move from the previous day.